… States Food and Drug Administration (FDA) for treatment of amyotrophic lateral sclerosis (ALS), …
Is the Subject Area "Amyotrophic lateral sclerosis" applicable to this article? Yes No …

… Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by …
when administering therapeutic drugs, such as continuous intraspinal delivery of therapeutic …

… There are currently only two FDA approved drugs for its treatment, and both offer mild …
treatment. dl-Potassium 2-(1-Hydroxypentyl)-benzoate (dlPHPB) is a novel drug for the treatment …

… and large molecule drugs. Advancing central nervous system drug delivery technologies …
unit to be leveraged for improved bench-to-bedside translation of novel stroke therapeutics. …

… stem cell therapies against the pathogenesis of PD and ALS. This review has also emphasized
different therapeutic strategies such as drug therapy, gene and immunization therapies, …

… Amyotrophic lateral sclerosis (ALS) is a fast progressing … greatly promote the drug
development and the treatment of this … pre-symptomatic evaluation of ALS therapeutic, which can …

… is currently no cure or even effective treatment for ALS, FTD or ALS/FTD, hence the great
interest in strategies aimed at identifying new therapeutic targets. Numerous cellular processes …

… cell therapies from bench to bedside. In this review, the final … brainstem and spinal cord,
amyotrophic lateral sclerosis (ALS) … the development of conventional drug therapies difficult. The …

… [Citation8–12] While stem cell therapy might be one such solution in the future, present
intervention essentially relies on the use of riluzole, that is, a pharmacological aid credited with …

… amyotrophic lateral sclerosis, specific cd markers and monocyte migration in osteoarthritis
and OA synovium, and finally the significance of digital twin technology for developing precise …